Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer

Muhammad A. Khattak, Amanda R. Townsend, Carol Beeke, Christos S. Karapetis, Colin Luke, Rob Padbury, Guy Maddern, David Roder, Timothy J. Price

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Age is a major risk factor for development of sporadic colorectal cancer but elderly patients are underrepresented in clinical trials and are potentially offered chemotherapy less often. Methods: Data were obtained from South Australian Clinical Registry for advanced colorectal cancer between 1st February 2006 and 9th September 2010. Patients who received chemotherapy were analysed to assess the impact of single versus combination chemotherapy and to assess the outcome in two age cohorts, age <70 years and ≥70 years. Results: Out of a total of 1745 patients in the database during this time period, 951 (54.5%) received systemic chemotherapy. 286 (30%) received first line therapy (median age 74 years) with single agent fluoropyrimidine and 643 patients (68%) received first line combination chemotherapy (median age 64 years). The median overall survival of patients receiving first line combination chemotherapy was 23.9 months compared to 17.2 months for those who received single agent fluoropyrimidine (p < 0.001). Combination chemotherapy was given to 81% of patients aged <70 years compared to 53% of those ≥70 years. There was no significant difference in median overall survival of patients receiving chemotherapy by age cohort, 21.3 months for age <70 years and 21.1 months for age ≥70 years (p = 0.4). Conclusion: Treatment outcomes are comparable in both the elderly and younger patients. Patients who received initial combination chemotherapy were younger and had a longer median overall survival. In our study, age appeared to influence the treatment choices but not necessarily outcome.

LanguageEnglish
Pages1293-1298
Number of pages6
JournalEuropean Journal of Cancer
Volume48
Issue number9
DOIs
Publication statusPublished - 1 Jun 2012

Keywords

  • Chemotherapy
  • Colorectal
  • Elderly
  • Registry
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Khattak, M. A., Townsend, A. R., Beeke, C., Karapetis, C. S., Luke, C., Padbury, R., ... Price, T. J. (2012). Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 48(9), 1293-1298. https://doi.org/10.1016/j.ejca.2011.09.029
Khattak, Muhammad A. ; Townsend, Amanda R. ; Beeke, Carol ; Karapetis, Christos S. ; Luke, Colin ; Padbury, Rob ; Maddern, Guy ; Roder, David ; Price, Timothy J. / Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. In: European Journal of Cancer. 2012 ; Vol. 48, No. 9. pp. 1293-1298.
@article{5b1ba1d1eaab4393a057cf5bab770beb,
title = "Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer",
abstract = "Background: Age is a major risk factor for development of sporadic colorectal cancer but elderly patients are underrepresented in clinical trials and are potentially offered chemotherapy less often. Methods: Data were obtained from South Australian Clinical Registry for advanced colorectal cancer between 1st February 2006 and 9th September 2010. Patients who received chemotherapy were analysed to assess the impact of single versus combination chemotherapy and to assess the outcome in two age cohorts, age <70 years and ≥70 years. Results: Out of a total of 1745 patients in the database during this time period, 951 (54.5{\%}) received systemic chemotherapy. 286 (30{\%}) received first line therapy (median age 74 years) with single agent fluoropyrimidine and 643 patients (68{\%}) received first line combination chemotherapy (median age 64 years). The median overall survival of patients receiving first line combination chemotherapy was 23.9 months compared to 17.2 months for those who received single agent fluoropyrimidine (p < 0.001). Combination chemotherapy was given to 81{\%} of patients aged <70 years compared to 53{\%} of those ≥70 years. There was no significant difference in median overall survival of patients receiving chemotherapy by age cohort, 21.3 months for age <70 years and 21.1 months for age ≥70 years (p = 0.4). Conclusion: Treatment outcomes are comparable in both the elderly and younger patients. Patients who received initial combination chemotherapy were younger and had a longer median overall survival. In our study, age appeared to influence the treatment choices but not necessarily outcome.",
keywords = "Chemotherapy, Colorectal, Elderly, Registry, Survival",
author = "Khattak, {Muhammad A.} and Townsend, {Amanda R.} and Carol Beeke and Karapetis, {Christos S.} and Colin Luke and Rob Padbury and Guy Maddern and David Roder and Price, {Timothy J.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.ejca.2011.09.029",
language = "English",
volume = "48",
pages = "1293--1298",
journal = "European Journal of Cancer Part A: General Topics",
issn = "0964-1947",
publisher = "Elsevier Limited",
number = "9",

}

Khattak, MA, Townsend, AR, Beeke, C, Karapetis, CS, Luke, C, Padbury, R, Maddern, G, Roder, D & Price, TJ 2012, 'Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer', European Journal of Cancer, vol. 48, no. 9, pp. 1293-1298. https://doi.org/10.1016/j.ejca.2011.09.029

Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. / Khattak, Muhammad A.; Townsend, Amanda R.; Beeke, Carol; Karapetis, Christos S.; Luke, Colin; Padbury, Rob; Maddern, Guy; Roder, David; Price, Timothy J.

In: European Journal of Cancer, Vol. 48, No. 9, 01.06.2012, p. 1293-1298.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer

AU - Khattak, Muhammad A.

AU - Townsend, Amanda R.

AU - Beeke, Carol

AU - Karapetis, Christos S.

AU - Luke, Colin

AU - Padbury, Rob

AU - Maddern, Guy

AU - Roder, David

AU - Price, Timothy J.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background: Age is a major risk factor for development of sporadic colorectal cancer but elderly patients are underrepresented in clinical trials and are potentially offered chemotherapy less often. Methods: Data were obtained from South Australian Clinical Registry for advanced colorectal cancer between 1st February 2006 and 9th September 2010. Patients who received chemotherapy were analysed to assess the impact of single versus combination chemotherapy and to assess the outcome in two age cohorts, age <70 years and ≥70 years. Results: Out of a total of 1745 patients in the database during this time period, 951 (54.5%) received systemic chemotherapy. 286 (30%) received first line therapy (median age 74 years) with single agent fluoropyrimidine and 643 patients (68%) received first line combination chemotherapy (median age 64 years). The median overall survival of patients receiving first line combination chemotherapy was 23.9 months compared to 17.2 months for those who received single agent fluoropyrimidine (p < 0.001). Combination chemotherapy was given to 81% of patients aged <70 years compared to 53% of those ≥70 years. There was no significant difference in median overall survival of patients receiving chemotherapy by age cohort, 21.3 months for age <70 years and 21.1 months for age ≥70 years (p = 0.4). Conclusion: Treatment outcomes are comparable in both the elderly and younger patients. Patients who received initial combination chemotherapy were younger and had a longer median overall survival. In our study, age appeared to influence the treatment choices but not necessarily outcome.

AB - Background: Age is a major risk factor for development of sporadic colorectal cancer but elderly patients are underrepresented in clinical trials and are potentially offered chemotherapy less often. Methods: Data were obtained from South Australian Clinical Registry for advanced colorectal cancer between 1st February 2006 and 9th September 2010. Patients who received chemotherapy were analysed to assess the impact of single versus combination chemotherapy and to assess the outcome in two age cohorts, age <70 years and ≥70 years. Results: Out of a total of 1745 patients in the database during this time period, 951 (54.5%) received systemic chemotherapy. 286 (30%) received first line therapy (median age 74 years) with single agent fluoropyrimidine and 643 patients (68%) received first line combination chemotherapy (median age 64 years). The median overall survival of patients receiving first line combination chemotherapy was 23.9 months compared to 17.2 months for those who received single agent fluoropyrimidine (p < 0.001). Combination chemotherapy was given to 81% of patients aged <70 years compared to 53% of those ≥70 years. There was no significant difference in median overall survival of patients receiving chemotherapy by age cohort, 21.3 months for age <70 years and 21.1 months for age ≥70 years (p = 0.4). Conclusion: Treatment outcomes are comparable in both the elderly and younger patients. Patients who received initial combination chemotherapy were younger and had a longer median overall survival. In our study, age appeared to influence the treatment choices but not necessarily outcome.

KW - Chemotherapy

KW - Colorectal

KW - Elderly

KW - Registry

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84861333288&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2011.09.029

DO - 10.1016/j.ejca.2011.09.029

M3 - Article

VL - 48

SP - 1293

EP - 1298

JO - European Journal of Cancer Part A: General Topics

T2 - European Journal of Cancer Part A: General Topics

JF - European Journal of Cancer Part A: General Topics

SN - 0964-1947

IS - 9

ER -

Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer. 2012 Jun 1;48(9):1293-1298. https://doi.org/10.1016/j.ejca.2011.09.029